Peripheral Arterial Disease Clinical Trial
Official title:
Prospective Investigation of The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease
Verified date | April 2020 |
Source | Merit Medical Systems, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a prospective, single-center, non-randomized phase 2, first-in-iliac artery study, to evaluate the safety and effectiveness of the WRAPSODY Stent Graft for the treatment of peripheral arterial occlusive disease in symptomatic subjects with de novo or restenotic lesions in the common iliac artery (CIA) and/or external iliac artery (EIA), including lesions at the aortic bifurcation.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 31, 2020 |
Est. primary completion date | September 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years and older |
Eligibility |
Inclusion Criteria: 1. Subject has signed informed consent 2. Subject is = 21 years of age 3. Subject is able and willing to comply with study requirements 4. Male, infertile female, or female practicing contraception and a negative pregnancy test within 7 days prior to the study procedure 5. Symptomatic claudication or rest pain without tissue loss, Rutherford category 2-4 6. Angiographic evidence of de novo or restenotic target lesion(s) in native vessels in the common and/or external iliac artery(ies) (multiple stenoses may exist within the target lesion) 7. Total lesion(s) length is = 110mm 8. Target lesion(s) is at least 3 cm from an existing stent or stent graft 9. At least 1 stenosis in the target vessel has = 50% stenosis 10. Target vessel diameter is between 4.6 and 14.4mm at angiographic screening for device placement 11. Adequate ipsilateral blood flow, including at least 1 patent (<50% stenotic) superficial femoral or profundal femoral artery 12. Full expansion of an appropriately sized (in the investigator's opinion) standard angioplasty balloon has been achieved during primary angioplasty at the target lesion prior to enrollment Exclusion Criteria: 1. Subject has undergone an intervention (surgical or percutaneous) in the target limb(s) <30 days from the date of the index study procedure 2. Subject has a surgical or percutaneous procedure in the target limb(s) planned within 30 days following the index study procedure 3. Previous or planned bypass surgery in the target limb(s) 4. Coronary intervention within 30 days prior to enrollment or planned within 12 months after index study procedure 5. Subject has had a stroke within 90 days prior to the index study procedure 6. Subject has had a transient ischemic attack within 30 days prior to the index study procedure 7. Uncorrectable coagulation disorder 8. Subject cannot receive heparin, dual antiplatelet treatment, or anticoagulant(s) appropriate in the opinion of the investigator 9. Condition unrelated to study anticipated to require indefinite anticoagulation 10. Evidence of blood borne infection 11. Hypersensitivity to nickel titanium alloy 12. Allergy to radiographic contrast material which cannot be adequately premedicated 13. Serum creatinine >2.5mg/dL 14. The subject is enrolled in another investigational study 15. Life expectancy is = 12 months 16. Active malignancy other than non-melanomatous skin cancer 17. Stenosis/restenosis is located within a previously placed stent or stent graft 18. Angiographic evidence of thrombus within or adjacent to the target lesion(s) 19. Aneurysmal dilation proximal or distal to the target lesion(s) that could interfere with placement of the study device 20. Abdominal aortic artery stent, if it could interfere with placement of the study device 21. Target lesion(s) are located such that the stent graft would prevent blood flow to the internal iliac artery, if patent 22. Lesions requiring atherectomy or ablation to facilitate stent graft delivery 23. Any other condition deemed exclusionary in the opinion of the investigator for documented reasons relating to the health and/or welfare of the subject |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Merit Medical Systems, Inc. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety endpoint of subjects free from specified adverse events | The primary study safety endpoint is the proportion of subjects free from a composite of device- or procedure-related death, myocardial infarction, or amputation above the metatarsals in the treated leg resulting from a vascular event, or device- or procedure-related serious adverse events within 4 weeks of the index procedure. | 4 weeks after placement of WRAPSODY stent graft | |
Primary | Effectiveness endpoint of subjects with improvement of Rutherford Category | The primary clinical effectiveness endpoint is the proportion of subjects with improvement of at least 1 Rutherford category within 4 weeks of the index procedure. Composite with Outcome 3. | 4 weeks after placement of WRAPSODY stent graft | |
Primary | Effectiveness endpoint of subjects with patency | The primary clinical effectiveness endpoint is the proportion of subjects with patency as evaluated by duplex ultrasound at 4 weeks after index procedure. Composite with Outcome 2. | 4 weeks after placement of WRAPSODY stent graft |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
Active, not recruiting |
NCT03987061 -
MOTIV Bioresorbable Scaffold in BTK Artery Disease
|
N/A | |
Recruiting |
NCT03506633 -
Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
|
N/A | |
Active, not recruiting |
NCT03506646 -
Dietary Nitrate Supplementation and Thermoregulation
|
N/A | |
Active, not recruiting |
NCT04677725 -
NEtwork to Control ATherothrombosis (NEAT Registry)
|
||
Recruiting |
NCT05961943 -
RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients
|
N/A | |
Recruiting |
NCT06047002 -
Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
|
||
Completed |
NCT03185052 -
Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach
|
N/A | |
Recruiting |
NCT05992896 -
A Study of Loco-Regional Liposomal Bupivacaine Injection
|
Phase 4 | |
Completed |
NCT04635501 -
AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial
|
N/A | |
Recruiting |
NCT04584632 -
The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery
|
N/A | |
Withdrawn |
NCT03538392 -
Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
|
||
Recruiting |
NCT02915796 -
Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty
|
Phase 1 | |
Active, not recruiting |
NCT02900924 -
Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
|
||
Completed |
NCT02901847 -
To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities.
|
N/A | |
Not yet recruiting |
NCT02455726 -
Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease
|
N/A | |
Not yet recruiting |
NCT02387450 -
Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication
|
Phase 2/Phase 3 | |
Withdrawn |
NCT02126540 -
Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries
|
N/A | |
Completed |
NCT02384980 -
Saving Life and Limb: FES for the Elderly With PAD
|
Phase 1 | |
Completed |
NCT02022423 -
Physical Activity Daily - An Internet-Based Walking Program for Patients With Peripheral Arterial Disease
|
N/A |